Lilly’s Omvoh highlighted that patients with Crohn’s disease maintained steroid-free remission for three years

Lilly has recently announced that the new long-term data from Eli Lilly showed Omvoh delivered durable efficacy through three years in adults with moderately to severely active Crohn’s disease. This data from the Phase 3 VIVID-2 open-label extension study were presented at the 21st Congress of the European Crohn’s and Colitis Organisation in Stockholm. Additional data presented from the Phase 3 VIVID-1 and LUCENT-3 clinical trials showed Omvoh-treated patients experienced minimal hospitalizations and surgeries across both major types of inflammatory bowel disease Omvoh is the first and only IL-23p19 inhibitor to show strong and durable efficacy over four years in UC and three years in Crohn’s disease, with proven reduction of disease complications.

“Too many people with inflammatory bowel disease never achieve lasting remission, leaving them vulnerable to cumulative damage from poorly controlled inflammation that can result in emergency hospitalizations or surgery,” said Adrienne Brown, executive vice president and president of Lilly Immunology. “Omvoh is redefining what durable disease control can look like, with long-term data showing patients treated with Omvoh stayed in remission and experienced fewer serious complications over three years, underscoring its potential to alter the course of the disease.”

In VIVID-2, patients who achieved an endoscopic response at one year with Omvoh in the Phase 3 VIVID-1 clinical trial experienced long-term efficacy, with the majority remaining in clinical and corticosteroid-free remission and sustaining bowel urgency improvements through three years of continuous Omvoh treatment.

“For people with Crohn’s disease, unpredictable flares and abdominal pain can persist when remission isn’t achieved or sustained. Additionally, ongoing symptoms like urgent trips to the bathroom and fatigue can continue to disrupt daily life when the disease is not adequately controlled,” said Edward Barnes, M.D. MPH, Associate Professor of Medicine, University of North Carolina at Chapel Hill. “Seeing more than 90% of patients maintain steroid-free remission through three years on consistent monthly dosing, with 80% also experiencing relief from the disruptive symptoms of bowel urgency, gives providers confidence in Omvoh for outcomes that can last.”

---

---

Related Topics and Keywords

Crohn's disease, Eli Lilly, elli lilly, Lilly's Omvoh™